GCLabs

Search for Test Items

GCG women's cancer NGS panel

GC Labs code	F155	Test Field	Human genetics
Compulsory forms	Oncology requisition and consent form, GC Genome Informed consent for genetic testing

GC Labs code

F155

Test Field

Human genetics

Compulsory forms

Oncology requisition and consent form, GC Genome Informed consent for genetic testing

Information

Test method	NGS (Next generation sequencing)
Specimen (mL)	EDTA WB 3.0
Specimen storage	Refrigerated
Specimen stability	Ambient (1 day), Refrigerated (3 days)
Test schedule	Mon-Fri
Analytical time (day)	12

Test method

NGS (Next generation sequencing)

Specimen (mL)

EDTA WB 3.0

Specimen storage

Refrigerated

Specimen stability

Ambient (1 day), Refrigerated (3 days)

Test schedule

Mon-Fri

Analytical time (day)

Reference range/Unit	[Whole Blood] See comments in the report
Clinical Significance	The majority of hereditary breast cancers are caused by mutations in the BRCA1 and BRCA2 genes. Up to 80% of women with mutations in this gene will develop breast cancer and up to 40% will develop ovarian cancer. Mutations in the TP53 gene also cause the autosomal dominant Li-Fraumeri syndrome, which is characterized by breast cancer that develops before menopause, along with sarcomas, brain tumors, leukemias, and adrenal cortical cancer that occur in childhood.
Remark

Reference range/Unit

 [Whole Blood]
See comments in the report

Clinical Significance

The majority of hereditary breast cancers are caused by mutations in the BRCA1 and BRCA2 genes. Up to 80% of women with mutations in this gene will develop breast cancer and up to 40% will develop ovarian cancer. Mutations in the TP53 gene also cause the autosomal dominant Li-Fraumeri syndrome, which is characterized by breast cancer that develops before menopause, along with sarcomas, brain tumors, leukemias, and adrenal cortical cancer that occur in childhood.

Remark